414 related articles for article (PubMed ID: 33092576)
1. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
2. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
3. Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.
Wang J; Guo W; Wang X; Tang X; Sun X; Ren T
Clin Cancer Res; 2023 Feb; 29(3):659-666. PubMed ID: 36374561
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
5. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
6. Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
Fan Y; Che X; Qu J; Hou K; Wen T; Li Z; Li C; Wang S; Xu L; Liu Y; Qu X
Ann Surg Oncol; 2019 Oct; 26(11):3745-3755. PubMed ID: 31087180
[TBL] [Abstract][Full Text] [Related]
7. Exosomes loaded with programmed death ligand-1 promote tumor growth by immunosuppression in osteosarcoma.
Zhang L; Xue L; Wu Y; Wu Q; Ren H; Song X
Bioengineered; 2021 Dec; 12(2):9520-9530. PubMed ID: 34699324
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
[TBL] [Abstract][Full Text] [Related]
9. LINC00657 activates PD-L1 to promote osteosarcoma metastasis via miR-106a.
Zhang J; Chou X; Zhuang M; Zhu C; Hu Y; Cheng D; Liu Z
J Cell Biochem; 2020 Oct; 121(10):4188-4195. PubMed ID: 31898338
[TBL] [Abstract][Full Text] [Related]
10. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer cells synergistically defend against CD8
Li D; Zhou X; Xu W; Chen Y; Mu C; Zhao X; Yang T; Wang G; Wei L; Ma B
Cancer Med; 2023 Aug; 12(15):16405-16415. PubMed ID: 37501397
[TBL] [Abstract][Full Text] [Related]
12. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
13. Exosomal miR-675 from metastatic osteosarcoma promotes cell migration and invasion by targeting CALN1.
Gong L; Bao Q; Hu C; Wang J; Zhou Q; Wei L; Tong L; Zhang W; Shen Y
Biochem Biophys Res Commun; 2018 Jun; 500(2):170-176. PubMed ID: 29626470
[TBL] [Abstract][Full Text] [Related]
14. PDL1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8
Chen J; Song Y; Miao F; Chen G; Zhu Y; Wu N; Pang L; Chen Z; Chen X
Cancer Sci; 2021 Sep; 112(9):3437-3454. PubMed ID: 34152672
[TBL] [Abstract][Full Text] [Related]
15. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
16. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response.
Chen G; Huang AC; Zhang W; Zhang G; Wu M; Xu W; Yu Z; Yang J; Wang B; Sun H; Xia H; Man Q; Zhong W; Antelo LF; Wu B; Xiong X; Liu X; Guan L; Li T; Liu S; Yang R; Lu Y; Dong L; McGettigan S; Somasundaram R; Radhakrishnan R; Mills G; Lu Y; Kim J; Chen YH; Dong H; Zhao Y; Karakousis GC; Mitchell TC; Schuchter LM; Herlyn M; Wherry EJ; Xu X; Guo W
Nature; 2018 Aug; 560(7718):382-386. PubMed ID: 30089911
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum-derived exosomal PD-L1 expression in patients with advanced pancreatic cancer.
Park SJ; Park JY; Shin K; Hong TH; Lee M; Kim Y; Kim IH
BMC Cancer; 2023 May; 23(1):389. PubMed ID: 37127565
[TBL] [Abstract][Full Text] [Related]
18. Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR.
Lin B; Tian T; Lu Y; Liu D; Huang M; Zhu L; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Mar; 60(14):7582-7586. PubMed ID: 33382182
[TBL] [Abstract][Full Text] [Related]
19. Personalized detection of circling exosomal PD-L1 based on Fe
Pang Y; Shi J; Yang X; Wang C; Sun Z; Xiao R
Biosens Bioelectron; 2020 Jan; 148():111800. PubMed ID: 31678824
[TBL] [Abstract][Full Text] [Related]
20. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
